GDC-0032 (taselisib)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for GDC-0032 (taselisib), covering 2016-11-02 to 2017-11-28. Get the full timeline:
Most recent: Clinical Trial Update: A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer [Phase 1]